Trial Profile

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (BREACH-TB)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 05 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bedaquiline (Primary)
Indications Tuberculosis
Focus Adverse reactions; Therapeutic Use
Acronyms BREACH-TB

Most Recent Events

12 May 2026 Status changed from not yet recruiting to recruiting.
27 Mar 2026 Planned initiation date changed from 1 Mar 2026 to 1 Jul 2026.
04 Mar 2026 Planned initiation date changed from 1 Feb 2026 to 1 Mar 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com